文献速递肝病

接受标准生活方式建议的儿童脂肪肝疾病进展

Progression of Fatty Liver Disease in Children Receiving Standard of Care Lifestyle Advice.
PubMed 文献 · Gastroenterology · 2020-07-23

该研究比较了122名参加两项安慰剂对照随机临床试验的儿童NAFLD患者配对肝活检结果,这些患儿均接受标准生活方式建议。平均随访1.6±0.4年,29%的患儿边缘区或确诊NASH缓解,18%的脂肪肝或边缘区NASH患儿进展为确诊NASH,纤维化改善者占34%、恶化者占23%。

要点

  • 儿童NAFLD患者接受标准生活方式建议后,约三分之一在2年内出现组织学进展。
  • NASH缓解与纤维化改善可发生,但纤维化恶化见于23%的患儿。
  • 进展至确诊NASH和/或纤维化与青少年年龄、基线腰围、转氨酶、胆固醇及随访中血糖控制恶化相关。

核心结论

  • 在临床试验安慰剂组中,约三分之一的儿童NAFLD患者在2年内出现组织学进展,与肥胖加重、血清转氨酶升高和血糖稳态丧失相关。

研究设计与样本

  • 研究比较了2005年至2015年间NASH临床研究网络两项双盲随机临床试验中122名(共139名)儿童NAFLD患者的配对肝活检,所有患儿接受安慰剂和标准生活方式建议。
  • 患儿中74%为男性,64%为白人,71%为西班牙裔,平均年龄13±3岁(范围8-17岁)。

主要发现

  • 入组时31%的患儿有确诊NASH,34%有边缘区1型NASH,13%有边缘区3型NASH,21%有脂肪肝但无NASH。
  • 平均1.6±0.4年随访期间,29%的患儿边缘区或确诊NASH缓解,18%的脂肪肝或边缘区NASH患儿进展为确诊NASH。
  • 纤维化改善见于34%的患儿,恶化见于23%。
  • 任何进展至确诊NASH和/或纤维化与基线青少年年龄、较高腰围、丙氨酸或天冬氨酸氨基转移酶水平、总胆固醇和低密度脂蛋白胆固醇相关(P<0.05)。
  • 随访期间,进展还与丙氨酸氨基转移酶升高、血红蛋白A1C升高(P<0.05)、γ-谷氨酰转移酶升高和2型糖尿病发生相关(P<0.01)。

关键数值与推荐

  • γ-谷氨酰转移酶水平升高与任何改善的几率降低相关(P=0.003)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) is the most common pediatric chronic liver disease. Little is known about outcomes in recognized youth. METHODS: We compared paired liver biopsies from 122 of 139 children with NAFLD (74% male; 64% white; 71% Hispanic; mean age, 13 ± 3 years; age range, 8-17 years) who received placebo and standard of care lifestyle advice in 2 double-blind, randomized clinical trials within the nonalcoholic steatohepatitis (NASH) clinical research network from 2005 through 2015. We analyzed histologic changes with respect to baseline and longitudinal change in clinical variables using regression analysis. RESULTS: At enrollment, 31% of the children had definite NASH, 34% had borderline zone 1 NASH, 13% had borderline zone 3 NASH, and 21% had fatty liver but not NASH. Over a mean period of 1.6 ± 0.4 years, borderline or definite NASH resolved in 29% of the children, whereas 18% of the children with fatty liver or borderline NASH developed definite NASH. Fibrosis improved in 34% of the children but worsened in 23%. Any progression to definite NASH and/or in fibrosis was associated with adolescent age, and higher waist circumference, levels of alanine or aspartate aminotransferase, total and low-density lipoprotein cholesterol at baseline (<0.05), and over follow-up time, with increasing level of alanine aminotransferase, hemoglobin A1C (P<.05), gamma-glutamyl transferase and development of type 2 diabetes (P<.01). Increasing level of gamma-glutamyl transferase was also associated with reduced odds of any improvement (P = .003). CONCLUSIONS: One-third of children with NAFLD enrolled in placebo groups of clinical trials had histologic features of progression within 2 years, in association with increasing obesity and serum levels of aminotransferases and loss of glucose homeostasis.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Xanthakos SA, Lavine JE, Yates KP, et al. Progression of Fatty Liver Disease in Children Receiving Standard of Care Lifestyle Advice. Gastroenterology. 2020. PMID: 32712103. doi:10.1053/j.gastro.2020.07.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。